Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.…
Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates
Tenaya Therapeutics (NASDAQ: TNYA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 70 employees.
The shares were at 0.2866 USD on 20 November 2026, down 78.8% over 52 weeks. Its 52-week range is 0.2800 USD to 1.560 USD: the price is 81.6% below the high and 2.4% above the low.
Its market capitalisation is 65.32M USD.
Tenaya Therapeutics reports return on equity of -73.5%.
It holds more cash than debt, a net cash position of 63.95M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 10 March 2027.